Abel, EL and Bilitzke, PJ (1990) A possible alarm substance in the forced swimming test. Physiology & Behavior 48, 233–239.
Antunes, MS, Ruff, JR, de Oliveira Espinosa, D, Piegas, MB, de Brito, ML, Rocha, KA, de Gomes, MG, Goes, AT, Souza, LC, Donato, F, Boeira, SP and Jesse, CR (2015) Neuropeptide Y administration reverses tricyclic antidepressant treatment-resistant depression induced by ACTH in mice. Hormones and Behavior 73, 56–63.
Appelhof, BC, Huyser, J, Verweij, M, Brouwer, JP, Van Dyck, R, Fliers, E, Hoogendijk, WJG, Tijssen, JGP, Wiersinga, WM and Schene, AH (2006) Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biological Psychiatry 59, 696–701.
Ardalan, M, Wegener, G, Polsinelli, B, Madsen, TM and Nyengaard, JR (2016) Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression. Hippocampus 26, 1414–1423.
Ardalan, M, Rafati, AH, Nyengaard, JR and Wegener, G (2017a) Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus. British Journal of Pharmacology 174, 483–492.
Ardalan, M, Wegener, G, Rafati, AH and Nyengaard, JR (2017b) S-Ketamine rapidly reverses synaptic and vascular deficits of hippocampus in genetic animal model of depression. The International Journal of Neuropsychopharmacology 20, 247–256.
Aubry, JM, Gervasoni, N, Osiek, C, Perret, G, Rossier, MF, Bertschy, G and Bondolfi, G (2007) The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. Journal of Psychiatric Research 41, 290–294.
Autry, AE, Adachi, M, Nosyreva, E, Na, ES, Los, MF, Cheng, PF, Kavalali, ET and Monteggia, LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91–96.
Bale, TL (2006) Stress sensitivity and the development of affective disorders. Hormones and Behavior 50, 529–33.
Ballard, ED, Ionescu, DF, Vande Voort, JL, Niciu, MJ, Richards, EM, Luckenbaugh, DA, Brutsche, NE, Ameli, R, Furey, ML and Zarate, CA Jr (2014) Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. Journal of Psychiatric Research 58, 161–166.
Baumeister, D, Lightman, SL and Pariante, CM (2016) The HPA axis in the pathogenesis and treatment of depressive disorders: integrating clinical and molecular findings. Psychopathology Review a3, 64–76.
Berman, RM, Cappiello, A, Anand, A, Oren, DA, Heninger, GR, Charney, DS and Krystal, JH (2000) Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351–354.
Brand, SJ and Harvey, BH (2017a) Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression I: bio-behavioural validation and response to imipramine. Acta Neuropsychiatrica 29, 193–206.
Brand, SJ and Harvey, BH (2017b) Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies. Acta Neuropsychiatrica 29, 207–221.
Browne, CA and Lucki, I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Frontiers in Pharmacology 4, 161.
Burgdorf, J, Kroes, RA, Zhang, XL, Gross, AL, Schmidt, M, Weiss, C, Disterhoft, JF, Burch, RM, Stanton, PK and Moskal, JR (2015a) Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats. Behavioural Brain Research 294, 177–185.
Burgdorf, J, Zhang, XL, Weiss, C, Matthews, E, Disterhoft, JF, Stanton, PK and Moskal, JR (2011) The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiology of Aging 32, 698–706.
Burgdorf, J, Zhang, XL, Nicholson, KL, Balster, RL, Leander, JD, Stanton, PK, Gross, AL, Kroes, RA and Moskal, JR (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38, 729–742.
Burgdorf, J, Zhang, XL, Weiss, C, Gross, A, Boikess, SR, Kroes, RA, Khan, MA, Burch, RM, Rex, CS, Disterhoft, JF, Stanton, PK and Moskal, JR (2015b) The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus. Neuroscience 308, 202–211.
Canuso, CM, Singh, JB, Fedgchin, M, Alphs, L, Lane, R, Lim, P, Pinter, C, Hough, D, Sanacora, G, Manji, H and Drevets, WC (2018) Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. The American Journal of Psychiatry 175, 620–630.
Cowen, PJ (2010) Not fade away: the HPA axis and depression. Psychological Medicine 40, 1–4.
Daly, EJ, Singh, JB, Fedgchin, M, Cooper, K, Lim, P, Shelton, RC, Thase, ME, Winokur, A, Van Nueten, L, Manji, H and Drevets, WC (2018) Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 75, 139–148.
du Jardin, KG, Liebenberg, N, Cajina, M, Muller, HK, Elfving, B, Sanchez, C and Wegener, G (2017) S-Ketamine mediates its acute and sustained antidepressant-like activity through a 5-HT1B receptor dependent mechanism in a genetic rat model of depression. Frontiers in Pharmacology 8, 978.
du Jardin, KG, Liebenberg, N, Muller, HK, Elfving, B, Sanchez, C and Wegener, G (2016a) Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology (Berl) 233, 2813–2825.
du Jardin, KG, Muller, HK, Sanchez, C, Wegener, G and Elfving, B (2016b) A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. European Journal of Pharmacology 786, 29–35.
Eskelund, A, Budac, DP, Sanchez, C, Elfving, B and Wegener, G (2016) Female flinders sensitive line rats show estrous cycle-independent depression-like behavior and altered tryptophan metabolism. Neuroscience 329, 337–348.
FDA (2019) FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic.
Fischer, CW, Eskelund, A, Budac, DP, Tillmann, S, Liebenberg, N, Elfving, B and Wegener, G (2015) Interferon-alpha treatment induces depression-like behaviour accompanied by elevated hippocampal quinolinic acid levels in rats. Behavioural Brain Research 293, 166–172.
Ghosal, S, Hare, BD and Duman, RS (2017) Prefrontal cortex GABAergic deficits and circuit dysfunction in the pathophysiology and treatment of chronic stress and depression. Current Opinion in Behavioral Sciences 14, 1–8.
Hindmarch, I (2002) Beyond the monoamine hypothesis: mechanisms, molecules and methods. European Psychiatry 17(Suppl 3), 294–299.
Jiang, Y, Wang, Y, Sun, X, Lian, B, Sun, H, Wang, G, Du, Z, Li, Q and Sun, L (2017) Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model. Brain and Behavior 7, e00749.
Joca, SR and Guimaraes, FS (2006) Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 185, 298–305.
Kellner, CH, Rubinow, DR, Gold, PW and Post, RM (1983) Relationship of cortisol hypersecretion to brain CT scan alterations in depressed patients. Psychiatry Research 8, 191–197.
Kessing, LV, Willer, IS and Knorr, U (2011) Volume of the adrenal and pituitary glands in depression. Psychoneuroendocrinology 36, 19–27.
Kessler, RC, Berglund, P, Demler, O, Jin, R, Koretz, D, Merikangas, KR, Rush, AJ, Walters, EE, Wang, PS and National Comorbidity Survey, R (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). The Journal of the American Medical Association 289, 3095–3105.
Kilkenny, C, Browne, WJ, Cuthill, IC, Emerson, M and Altman, DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Journal of Pharmacology & Pharmacotherapeutics 1, 94–99.
Kitamura, Y, Araki, H and Gomita, Y (2002) Influence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacology Biochemistry and Behavior 71, 63–69.
Kitamura, Y, Fujitani, Y, Kitagawa, K, Miyazaki, T, Sagara, H, Kawasaki, H, Shibata, K, Sendo, T and Gomita, Y (2008) Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biological and Pharmaceutical Bulletin 31, 246–249.
Li, N, Lee, B, Liu, RJ, Banasr, M, Dwyer, JM, Iwata, M, Li, XY, Aghajanian, G and Duman, RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964.
Li, N, Liu, RJ, Dwyer, JM, Banasr, M, Lee, B, Son, H, Li, XY, Aghajanian, G and Duman, RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biological Psychiatry 69, 754–761.
Liebenberg, N, Joca, S and Wegener, G (2015) Nitric oxide involvement in the antidepressant-like effect of ketamine in the Flinders sensitive line rat model of depression. Acta Neuropsychiatrica 27, 90–96.
Machado-Vieira, R, Salvadore, G, Diazgranados, N and Zarate, CA Jr (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology & Therapeutics 123, 143–150.
McAllister-Williams, RH, Ferrier, IN and Young, AH (1998) Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychological Medicine 28, 573–584.
McEwen, BS (2004) Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Annals of the New York Academy of Sciences 1032, 1–7.
Moskal, JR, Burgdorf, JS, Stanton, PK, Kroes, RA, Disterhoft, JF, Burch, RM and Amin Khan, M (2016) The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Current Neuropharmacology 15(1), 47–56.
NCT03560518 (2019) Study of rapastinel as monotherapy in patients with MDD: NCT03560518. ClinicalTrials.gov.
Nestler, EJ, Barrot, M, DiLeone, RJ, Eisch, AJ, Gold, SJ and Monteggia, LM (2002) Neurobiology of depression. Neuron 34, 13–25.
Pereira, VS, Romano, A, Wegener, G and Joca, SR (2015) Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test. Psychopharmacology (Berl) 232, 2263–2273.
Porsolt, RD, Le Pichon, M and Jalfre, M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730–732.
Quarton, GC, Clark, LD, Cobb, S and Bauer, W (1955) Mental disturbances associated with acth and cortisone: a review of explanatory hypotheses. Medicine (United States) 34, 13–50.
Ragguett, R-M, Rong, C, Kratiuk, K and McIntyre, RS (2019) Rapastinel – an investigational NMDA-R modulator for major depressive disorder: evidence to date. Expert Opinion on Investigational Drugs 28, 113–119.
Sales, AJ, Biojone, C, Terceti, MS, Guimaraes, FS, Gomes, MV and Joca, SR (2011) Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. British Journal of Pharmacology 164, 1711–1721.
Samuels, BA, Leonardo, ED, Gadient, R, Williams, A, Zhou, J, David, DJ, Gardier, AM, Wong, EH and Hen, R (2011) Modeling treatment-resistant depression. Neuropharmacology 61, 408–413.
Sanacora, G and Schatzberg, AF (2015) Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40, 259–267.
Silva Pereira, V, Elfving, B, Joca, SRL and Wegener, G (2017) Ketamine and aminoguanidine differentially affect BDNF and MTOR gene expression in the prefrontal cortex of adult male rats. European Journal of Pharmacology 815, 304–311.
Sorrells, SF, Caso, JR, Munhoz, CD and Sapolsky, RM (2009) The stressed CNS: when glucocorticoids aggravate inflammation. Neuron 64, 33–39.
Trevino, K, McClintock, SM, McDonald Fischer, N, Vora, A and Husain, MM (2014) Defining treatment-resistant depression: a comprehensive review of the literature. Annals of Clinical Psychiatry 26, 222–232.
Walker, AJ, Burnett, SA, Hasebe, K, McGillivray, JA, Gray, LJ, McGee, SL, Walder, K, Berk, M and Tye, SJ (2013) Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels. Behavioural Brain Research 242, 76–83.
Walker, AJ, Foley, BM, Sutor, SL, McGillivray, JA, Frye, MA and Tye, SJ (2015) Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Behavioural Brain Research 293, 198–202.
Willner, P and Belzung, C (2015) Treatment-resistant depression: are animal models of depression fit for purpose? Psychopharmacology (Berl) 232, 3473–3495.
World Health Organization (WHO) (2018) Depression –Fact Sheet. Geneva: World Health Organization.
Yang, B, Zhang, JC, Han, M, Yao, W, Yang, C, Ren, Q, Ma, M, Chen, QX and Hashimoto, K (2016) Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 233, 3647–3657.
Young, EA, Altemus, M, Lopez, JF, Kocsis, JH, Schatzberg, AF, DeBattista, C and Zubieta, JK (2004) HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 29, 1198–1204.
Zanos, P, Moaddel, R, Morris, PJ, Georgiou, P, Fischell, J, Elmer, GI, Alkondon, M, Yuan, P, Pribut, HJ, Singh, NS, Dossou, KS, Fang, Y, Huang, XP, Mayo, CL, Wainer, IW, Albuquerque, EX, Thompson, SM, Thomas, CJ, Zarate, CA Jr and Gould, TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481–486.
Zarate, C, Duman, RS, Liu, G, Sartori, S, Quiroz, J and Murck, H (2013) New paradigms for treatment-resistant depression. Annals of the New York Academy of Sciences 1292, 21–31.
Zarate, CA Jr, Singh, JB, Carlson, PJ, Brutsche, NE, Ameli, R, Luckenbaugh, DA, Charney, DS and Manji, HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives Of General Psychiatry 63, 856–864.
Zhu, X, Ye, G, Wang, Z, Luo, J and Hao, X (2017) Sub-anesthetic doses of ketamine exert antidepressant-like effects and upregulate the expression of glutamate transporters in the hippocampus of rats. Neuroscience Letters 639, 132–137.
Zobel, AW, Nickel, T, Künzel, HE, Ackl, N, Sonntag, A, Ising, M and Holsboer, F (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research 34, 171–181.
Zorumski, CF, Nagele, P, Mennerick, S and Conway, CR (2015) Treatment-resistant major depression: rationale for NMDA receptors as targets and nitrous oxide as therapy. Frontiers in Psychiatry 6, 172.